Literature DB >> 25445163

Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.

Antonio Tursi1, Walter Elisei, Marcello Picchio, GianMarco Giorgetti, Giovanni Brandimarte.   

Abstract

BACKGROUND: Anti-TNFα antibodies are effective in treating inflammatory bowel diseases (IBDs) unresponsive to the standard treatments. Information about the role of rapid fecal calprotectin (FC) in monitoring ambulatory IBD patients under treatment with anti-TNFα is lacking. Our aim was to assess the accuracy of rapid FC in monitoring those patients.
METHODS: Seventy-two patients (38 males, 34 females, mean age 42.5 years, range 23-57 years), affected by ulcerative colitis (UC) (20 patients) or by Crohn's disease (CD) (52 patients) were treated with anti-TNFα antibodies. FC was assessed by a rapid semiquantitative test.
RESULTS: With respect to the absence of clinical remission, FC test showed sensitivity of 71.8 %, specificity of 65.2 %, PPV of 41.8 %, and NPV of 86.9 %. In UC patients, FC test showed a sensitivity of 66.7 %, a specificity of 56.1 %, a PPV of 18.2 %, and a NPV of 92.0 %. In CD patients, FC test showed sensitivity of 70.6 %, specificity of 65.2 %, PPV of 50.0 %, and NPV of 81.8 %. With respect to the presence of endoscopic lesions, FC test showed sensitivity of 73.5 %, specificity of 96.0 %, PPV of 96.2 %, and NPV of 72.7 %. In UC patients, FC test showed sensitivity of 47.2 %, specificity of 84.6 %, PPV of 89.5 %, and NPV of 36.7 %. In CD patients, FC test showed sensitivity of 90.1 %, specificity of 79.7 %, PPV of 71.9 %, and NPV of 93.3 %.
CONCLUSIONS: Diagnostic accuracy of rapid FC seems better in predicting persistence of endoscopic lesions than clinical remission in IBD patients under treatment with anti-TNFα.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25445163     DOI: 10.1007/s10620-014-3459-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  39 in total

1.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

2.  Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.

Authors:  Lamia Kallel; Imen Ayadi; Samira Matri; Monia Fekih; Nadia Ben Mahmoud; Moncef Feki; Sami Karoui; Bechir Zouari; Jalel Boubaker; Naziha Kaabachi; Azza Filali
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-03       Impact factor: 2.566

3.  Evaluation of the Quantum Blue® rapid test for faecal calprotectin.

Authors:  Julie Wassell; Michael Wallage; Ella Brewer
Journal:  Ann Clin Biochem       Date:  2011-09-19       Impact factor: 2.057

4.  A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis.

Authors:  Triana Lobatón; Francisco Rodríguez-Moranta; Alicia Lopez; Elena Sánchez; Lorena Rodríguez-Alonso; Jordi Guardiola
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

5.  Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease?

Authors:  A Tursi
Journal:  Aliment Pharmacol Ther       Date:  2013-04       Impact factor: 8.171

6.  Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study.

Authors:  F Rizzello; P Gionchetti; A D'Arienzo; F Manguso; G Di Matteo; V Annese; D Valpiani; T Casetti; S Adamo; A Prada; G N Castiglione; G Varoli; M Campieri
Journal:  Aliment Pharmacol Ther       Date:  2002-06       Impact factor: 8.171

7.  Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.

Authors:  Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Ekaterina Safroneeva; Yvonne Romero; David Armstrong; Carsten Schmidt; Michael Trummler; Valérie Pittet; Stephan R Vavricka
Journal:  Inflamm Bowel Dis       Date:  2013-02       Impact factor: 5.325

8.  Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases.

Authors:  A Damms; S C Bischoff
Journal:  Int J Colorectal Dis       Date:  2008-07-16       Impact factor: 2.571

9.  Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.

Authors:  Taina Sipponen; Erkki Savilahti; Kaija-Leena Kolho; Hannu Nuutinen; Ulla Turunen; Martti Färkkilä
Journal:  Inflamm Bowel Dis       Date:  2008-01       Impact factor: 5.325

10.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

View more
  3 in total

1.  Hydrostatin-TL1, an Anti-Inflammatory Active Peptide from the Venom Gland of Hydrophis cyanocinctus in the South China Sea.

Authors:  Ningyuan Wang; Yan Huang; An Li; Hailong Jiang; Jie Wang; Jianzhong Li; Lei Qiu; Ka Li; Yiming Lu
Journal:  Int J Mol Sci       Date:  2016-11-22       Impact factor: 5.923

Review 2.  From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.

Authors:  Maria Gloria Mumolo; Lorenzo Bertani; Linda Ceccarelli; Gabriella Laino; Giorgia Di Fluri; Eleonora Albano; Gherardo Tapete; Francesco Costa
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

3.  Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.

Authors:  Elham A Hassan; Haidi K Ramadan; Ali A Ismael; Khaled F Mohamed; Madiha M El-Attar; Ihab Alhelali
Journal:  Saudi J Gastroenterol       Date:  2017 Jul-Aug       Impact factor: 2.485

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.